Search hospitals > Oregon > Portland
Oregon Health and Science University
Claim this profilePortland, Oregon 97239
Global Leader in Cancer
Global Leader in Solid Tumors
Conducts research for Leukemia
Conducts research for Lung Cancer
Conducts research for Lymphoma
2374 reported clinical trials
191 medical researchers
Summary
Oregon Health and Science University is a medical facility located in Portland, Oregon. This center is recognized for care of Cancer, Solid Tumors, Leukemia, Lung Cancer, Lymphoma and other specialties. Oregon Health and Science University is involved with conducting 2,374 clinical trials across 2,389 conditions. There are 191 research doctors associated with this hospital, such as Katrina Winsnes, Christopher W. Ryan, Bill Chang, and Matthew Taylor, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Solid Tumors
Global LeaderStage IV
Stage III
RET
Top PIs
Katrina WinsnesOregon Health and Science University8 years of reported clinical research
Expert in Cancer
Expert in Soft Tissue Sarcoma
26 reported clinical trials
46 drugs studied
Christopher W. RyanOregon Health and Science University3 years of reported clinical research
Studies Cancer
Studies Kidney Cancer
23 reported clinical trials
70 drugs studied
Bill ChangOregon Health and Science University8 years of reported clinical research
Studies Acute Lymphoblastic Leukemia
Studies Leukemia
23 reported clinical trials
51 drugs studied
Matthew Taylor, MDProvidence Portland Medical Center5 years of reported clinical research
Studies Melanoma
Studies Non-Small Cell Lung Cancer
20 reported clinical trials
36 drugs studied
Clinical Trials running at Oregon Health and Science University
Multiple Myeloma
Cancer
Pancreatic Cancer
Cystic Fibrosis
Carcinoid Tumor
Bladder Cancer
Chronic Myeloid Leukemia
Pneumonia
Urinary Tract Infection
Acute Myelogenous Leukemia
Iberdomide Combo
for Multiple Myeloma
Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to deploy novel agents with complementary mechanism of action and favorable toxicity profile to reach and maintain MRD (-) status. Given its favorable toxicity profile, the convenience of oral administration, and compelling single agent activity even in heavily pretreated MM, iberdomide is likely amenable to long term therapy in patients with high-risk of relapse/progression identified by the persistence of MRD(+). The investigators intend to develop combination(s) of iberdomide with other agents with complementary mechanism of action in the consolidation setting post AHCT in order to achieve and sustain MRD (-).
Recruiting3 awards Phase 1 & 214 criteria
Tec-DR and Tal-DR
for Multiple Myeloma
This trial is testing two new drug combinations to see if they work better than the current standard treatment for multiple myeloma. The new treatments aim to help the immune system find and destroy cancer cells more effectively.
Recruiting2 awards Phase 35 criteria
Lenalidomide + Dexamethasone +/- Daratumumab
for Multiple Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
Recruiting2 awards Phase 312 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Oregon Health and Science University?
Oregon Health and Science University is a medical facility located in Portland, Oregon. This center is recognized for care of Cancer, Solid Tumors, Leukemia, Lung Cancer, Lymphoma and other specialties. Oregon Health and Science University is involved with conducting 2,374 clinical trials across 2,389 conditions. There are 191 research doctors associated with this hospital, such as Katrina Winsnes, Christopher W. Ryan, Bill Chang, and Matthew Taylor, MD.
Where is Oregon Health and Science University located?
The Oregon Health and Science University (OHSU) Hospital is situated in southwest Portland, OR, mainly on the Marquam Hill Campus. Its primary facility, OHSU Hospital, is located at 3181 SW Sam Jackson Park Rd, Portland, OR 97239.
Who should I call to ask about financial aid or insurance network?
**Oregon Health and Science University (OHSU) Hospital Financial and Insurance Assistance Contacts:**
- **Financial Assistance:**
- Phone: 503-494-8551 (Weekdays 8 a.m. to 4:30 p.m.)
- **Payment Plans:**
- OHSU and Hillsboro Medical Center: 866-617-6855
- Adventist Health Portland: 503-261-6095
- **General Inquiries:**
- Phone: 503-494-8551 or 888-311-1283
- **Insurance-Related Matters:**
- Oregon Health Plan (Medicaid & CHIP): 800-699-9075
- Email: [OHP Contact Email]
- Phone: 1-800-273-0557
- Mail: PO Box 14015, Salem, OR 97309
What insurance does Oregon Health and Science University accept?
Oregon Health and Science University (OHSU) accepts various insurance plans, including original Medicare. For specific coverage limitations, contact the Patient Estimate Team at 503-494-3508 or use the online price estimate tool. OHSU has arrangements with networks like PacificSource for student health insurance and offers resources for navigating insurance appeals and denials.
What awards or recognition has Oregon Health and Science University received?
Oregon Health and Science University (OHSU) in Portland, Oregon, is renowned for its research and care, earning the title of "Special Focus - Research Institution" by the Carnegie Classification. It excels in cancer research, cardiovascular medicine, ophthalmology, and pediatric care. OHSU also benefits from substantial research funding, with awards and grants provided by the Medical Research Foundation.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.